139 related articles for article (PubMed ID: 27136424)
1. Clinical response of masitinib mesylate in the treatment of canine macroscopic mast cell tumours.
Grant J; North S; Lanore D
J Small Anim Pract; 2016 Jun; 57(6):283-90. PubMed ID: 27136424
[TBL] [Abstract][Full Text] [Related]
2. Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.
Smrkovski OA; Essick L; Rohrbach BW; Legendre AM
Vet Comp Oncol; 2015 Sep; 13(3):314-21. PubMed ID: 23845124
[TBL] [Abstract][Full Text] [Related]
3. Masitinib is safe and effective for the treatment of canine mast cell tumors.
Hahn KA; Ogilvie G; Rusk T; Devauchelle P; Leblanc A; Legendre A; Powers B; Leventhal PS; Kinet JP; Palmerini F; Dubreuil P; Moussy A; Hermine O
J Vet Intern Med; 2008; 22(6):1301-9. PubMed ID: 18823406
[TBL] [Abstract][Full Text] [Related]
4. A retrospective review of treatment and response of high-risk mast cell tumours in dogs.
Miller RL; Van Lelyveld S; Warland J; Dobson JM; Foale RD
Vet Comp Oncol; 2016 Dec; 14(4):361-370. PubMed ID: 25223579
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors.
Hahn KA; Legendre AM; Shaw NG; Phillips B; Ogilvie GK; Prescott DM; Atwater SW; Carreras JK; Lana SE; Ladue T; Rusk A; Kinet JP; Dubreuil P; Moussy A; Hermine O
Am J Vet Res; 2010 Nov; 71(11):1354-61. PubMed ID: 21034327
[TBL] [Abstract][Full Text] [Related]
6. Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial.
Cadot P; Hensel P; Bensignor E; Hadjaje C; Marignac G; Beco L; Fontaine J; Jamet JF; Georgescu G; Campbell K; Cannon A; Osborn SC; Messinger L; Gogny-Goubert M; Dubreuil P; Moussy A; Hermine O
Vet Dermatol; 2011 Dec; 22(6):554-64. PubMed ID: 21668810
[TBL] [Abstract][Full Text] [Related]
7. Prospective clinical trial of masitinib mesylate treatment for advanced stage III and IV canine malignant melanoma.
Giuliano A; Dobson J
J Small Anim Pract; 2020 Mar; 61(3):190-194. PubMed ID: 31960455
[TBL] [Abstract][Full Text] [Related]
8. "Masitinib" is safe and effective for the treatment of canine mast cell tumors.
Gentilini F
J Vet Intern Med; 2010; 24(1):6; author reply 7. PubMed ID: 20391634
[No Abstract] [Full Text] [Related]
9. The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs.
Gentilini F; Turba ME; Dally C; Takanosu M; Kurita S; Bonkobara M
BMC Vet Res; 2020 Feb; 16(1):64. PubMed ID: 32075643
[TBL] [Abstract][Full Text] [Related]
10. In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines.
Lyles SE; Milner RJ; Kow K; Salute ME
Vet Comp Oncol; 2012 Sep; 10(3):223-35. PubMed ID: 22594682
[TBL] [Abstract][Full Text] [Related]
11. Development and progression of proteinuria in dogs treated with masitinib for neoplasia: 28 cases (2010-2019).
Kuijlaars M; Helm J; McBrearty A
J Small Anim Pract; 2021 Aug; 62(8):646-654. PubMed ID: 33634470
[TBL] [Abstract][Full Text] [Related]
12. Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumours: 21 cases.
Taylor F; Gear R; Hoather T; Dobson J
J Small Anim Pract; 2009 Jun; 50(6):284-9. PubMed ID: 19527421
[TBL] [Abstract][Full Text] [Related]
13. Presumed masitinib-induced nephrotic syndrome and azotemia in a dog.
Devine L; Polzin DJ
Can Vet J; 2016 Jul; 57(7):752-6. PubMed ID: 27429464
[TBL] [Abstract][Full Text] [Related]
14. Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro.
Milovancev M; Helfand SC; Marley K; Goodall CP; Löhr CV; Bracha S
BMC Vet Res; 2016 Jun; 12():85. PubMed ID: 27259510
[TBL] [Abstract][Full Text] [Related]
15. Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases.
Cooper M; Tsai X; Bennett P
Vet Comp Oncol; 2009 Sep; 7(3):196-206. PubMed ID: 19691648
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and safety of a water-soluble micellar paclitaxel (Paccal Vet) in canine mastocytomas.
Rivera P; Akerlund-Denneberg N; Bergvall K; Kessler M; Rowe A; Willmann M; Persson G; Kastengren Fröberg G; Westberg S; von Euler H
J Small Anim Pract; 2013 Jan; 54(1):20-7. PubMed ID: 23190121
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
Le Cesne A; Blay JY; Bui BN; Bouché O; Adenis A; Domont J; Cioffi A; Ray-Coquard I; Lassau N; Bonvalot S; Moussy A; Kinet JP; Hermine O
Eur J Cancer; 2010 May; 46(8):1344-51. PubMed ID: 20211560
[TBL] [Abstract][Full Text] [Related]
18. Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011-2018.
Lew FH; McQuown B; Borrego J; Cunningham S; Burgess KE
Vet Comp Oncol; 2019 Dec; 17(4):465-471. PubMed ID: 31069932
[TBL] [Abstract][Full Text] [Related]
19. Canine intranasal tumours treated with alternating carboplatin and doxorubin in conjunction with oral piroxicam: 29 cases.
Woodruff MJ; Heading KL; Bennett P
Vet Comp Oncol; 2019 Mar; 17(1):42-48. PubMed ID: 30146732
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the therapeutic potential of masitinib and expression of its specific targets c-Kit, PDGFR-α, PDGFR-β, and Lyn in canine prostate cancer cell lines.
Klose K; Packeiser EM; Granados-Soler JL; Hewicker-Trautwein M; Murua Escobar H; Nolte I
Vet Comp Oncol; 2022 Sep; 20(3):641-652. PubMed ID: 35384248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]